Utfall av byte till bevacizumab efter initial behandling med aflibercept mot åldersrelaterad makuladegeneration

Sammanfattning: Introduction Age-related macular degeneration (AMD) is an eye disease that can cause severe vision loss. At present there is no curative treatment. However, anti-vascular endothelial growth factor (VEGF) can slow down the process and prevent blindness. Ranibizumab and aflibercept are registered anti- VEGF drugs for AMD but more expensive compared to bevacizumab that is used off-label. Previous studies show no significant differences between the three drugs. Aim The aim was to study the outcome of switching to bevacizumab, after initial treatment with aflibercept, in terms of visual acuity and central retinal thickness. Material and methods This retrospective case-control study included 26 cases and 28 controls. The cases were initially treated with aflibercept and then with bevacizumab and the controls were only treated with aflibercept. Data was selected from the Swedish Macula Registry and from medical records at Örebro University Hospital. Results The treatment with bevacizumab is non-inferior compared to aflibercept when it comes to achieving successful scores for visual acuity, z=2,4 >